Advancing Robotics in Structural Heart Surgery
Capstan Medical has raised $110 million in an oversubscribed Series C round to propel its robotics platform for structural heart surgeries. Led by Eclipse, with support from Yu Galaxy, Intuitive Ventures, and newcomer Gideon Strategic Partners, the funding boosts Capstan’s total capital to over $150 million.
Key Highlights:
- Focus: Development of a surgical robot and catheter-delivered implants for minimally invasive mitral and tricuspid valve replacements.
- Milestones: First-in-human mitral valve procedure expected in early 2025, with a tricuspid procedure planned for 2025.
- Pivotal Trial Timeline: Targeting 2026, with FDA submission anticipated by 2028.
Expanding Innovation
“This funding fuels innovation and allows us to advance our mitral and tricuspid programs,” said CEO Maggie Nixon. Capstan aims to offer a less invasive alternative for patients ineligible for open-heart or standard catheter-based procedures.
Backing From Industry Leaders
Eclipse Partner Justin Butler praised Capstan’s transformative potential:
“Robotics will play a critical role in structural heart disease solutions. Capstan leads this wave with innovative robotic technology.”
Strategic Vision:
Capstan plans to scale operations, strengthen its team, and advance its mitral valve program as a top priority while progressing tricuspid development.
Follow MEDWIRE.AI for updates on transformative innovations in structural heart surgery and medical robotics.
